Novel platinum therapeutics induce rapid cancer cell death through triggering intracellular ROS storm

Area of Science:

• Biochemistry
• Nanotechnology
• Oncology

Background:

• Reactive oxygen species (ROS) production is crucial for cancer treatment, but current inducers have limited efficacy due to insufficient ROS generation.
• Platinum-based drugs are widely used in chemotherapy, primarily acting through DNA intercalation to induce apoptosis.

Purpose of the Study:

• To design and evaluate a novel platinum (Pt)-based drug, carrier-platin, for enhanced cancer treatment through ROS induction.
• To investigate the mechanism of action and anti-tumor efficacy of carrier-platin, particularly against multidrug-resistant cancers.

Main Methods:

• Development of carrier-platin, a drug integrating ultrasmall Pt-based nanoparticles within a poly(amino acids) carrier.
• Assessment of ROS production, cancer cell death patterns, and anti-tumor efficacy in vitro and in vivo.
• Comparison of carrier-platin's mechanism with traditional Pt-based drugs, focusing on DNA damage and cell death pathways.

Main Results:

• Carrier-platin dramatically triggered a burst of ROS in cancer cells, causing cell death within 30 minutes.
• Carrier-platin induced a unique cell death pattern, distinct from apoptosis or ferroptosis, independent of DNA damage.
• Demonstrated superior anti-tumor efficacy against a broad spectrum of cancers, including multidrug-resistant types, with minimal systemic toxicity.

Conclusions:

• Carrier-platin represents a novel class of anti-cancer therapeutics with a distinct mechanism of action based on potent ROS catalytic activity.
• The drug's ability to induce rapid cancer cell death and overcome multidrug resistance highlights its therapeutic potential.
• Findings reveal a new role for platinum in cancer cell eradication beyond DNA damage, paving the way for innovative chemotherapy strategies.